Published in Ann Oncol on June 01, 1999
Chemical Stability of Telavancin in Elastomeric Pumps. Curr Ther Res Clin Exp (2015) 0.83
Drug overdose due to malfunction of a patient-controlled analgesia machine -A case report-. Korean J Anesthesiol (2013) 0.75
The flow Rate Accuracy of Elastomeric Infusion Pumps After Repeated Filling. Anesth Pain Med (2014) 0.75
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer (2001) 2.67
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
More is not always better: a case for low-dose leucovorin. J Clin Oncol (1993) 2.03
Prognostic factors in metastatic breast cancer. Cancer Clin Trials (1981) 1.96
Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol (2003) 1.94
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood (1992) 1.36
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics (1989) 1.28
Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest (1995) 1.25
Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst (2000) 1.19
Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ (2002) 1.16
Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol (1994) 1.10
Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol (1992) 1.10
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ (2007) 1.09
Assessment of clonality in human tumors: a review. Cancer Res (1990) 1.08
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene (2012) 1.08
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene (2006) 1.06
Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? Ann Oncol (1999) 1.05
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ (2009) 0.99
A myeloperoxidase cDNA clone identifies an EcoRV RFLP. Nucleic Acids Res (1990) 0.97
Success and relapse rate after treatment of cryptorchidism with intranasal LHRH. Acta Paediatr Scand (1985) 0.94
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol (2007) 0.94
Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer (2001) 0.94
Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993. J Clin Microbiol (1996) 0.93
DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene (2008) 0.93
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity. Oncogene (2008) 0.93
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res (1999) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia (2010) 0.91
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer (2001) 0.90
Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. Genomics (1996) 0.90
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol (1997) 0.89
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. J Clin Psychiatry (1986) 0.89
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol (1999) 0.88
Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol (1993) 0.88
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer (2004) 0.88
Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int J Oncol (1997) 0.87
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1998) 0.86
Coagulation markers predict survival in cancer patients. Thromb Haemost (2002) 0.86
Spontaneous apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (1999) 0.86
Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. Mol Cell Probes (1997) 0.86
The enigma of young age. Ann Oncol (2006) 0.86
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol (2011) 0.85
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother (1997) 0.85
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol (2002) 0.85
Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells. Leukemia (1997) 0.85
Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers. Cancer Res (1995) 0.85
Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood (1993) 0.85
L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther (1991) 0.84
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant (1999) 0.84
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol (2009) 0.84
Expression of TCL1 in hematologic disorders. Pathobiology (2001) 0.84
Spontaneous massive abdominal wall hematoma in polycythemia vera. Acta Haematol (1985) 0.84
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.84
Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias. Blood (1996) 0.84
Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim Biophys Acta (1995) 0.83
Studying clonal heterogeneity in human cancers. Cancer Res (1993) 0.83
Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Leuk Lymphoma (2001) 0.83
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer (2000) 0.83
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol (2004) 0.82
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab (1993) 0.82
Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int J Pancreatol (1998) 0.82
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82
The two faces of p73. Cell Death Differ (2002) 0.82
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1997) 0.82
Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab (1994) 0.82
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC). Int J Cancer (1992) 0.81
Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol (2005) 0.81
The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Ann Oncol (2007) 0.81
Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells. J Natl Cancer Inst (1999) 0.81
The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells. Br J Haematol (1999) 0.81
Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol (1993) 0.80
Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemia. Neurosci Lett (1994) 0.80
Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. Cancer Chemother Pharmacol (2001) 0.80
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol (2008) 0.80
PRO_10--a new tissue-based prognostic multigene marker in patients with early estrogen receptor-positive breast cancer. Pathobiology (2011) 0.80